|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Manfredi S, Lepage C, Hatem C, Coatmeur O,
Faivre J and Bouvier AM: Epidemiology and management of liver
metastases from colorectal cancer. Ann Surg. 244:254–259. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spratlin JL, Mulder KE and Mackey JR:
Ramucirumab (IMC-1121B): A novel attack on angiogenesis. Future
Oncol. 6:1085–1094. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tabernero J, Yoshino T, Cohn AL,
Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy
DC, Van Cutsem E, Grothey A, et al: Ramucirumab versus placebo in
combination with second-line FOLFIRI in patients with metastatic
colorectal carcinoma that progressed during or after first-line
therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
(RAISE): A randomised, double-blind, multicentre, phase 3 study.
Lancet Oncol. 16:499–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R,
Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, et al:
Ramucirumab versus placebo as second-line treatment in patients
with advanced hepatocellular carcinoma following first-line therapy
with sorafenib (REACH): A randomised, double-blind, multicentre,
phase 3 trial. Lancet Oncol. 16:859–870. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arnold D, Lueza B, Douillard JY, Peeters
M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP,
Tabernero J, et al: Prognostic and predictive value of primary
tumour side in patients with RAS wild-type metastatic colorectal
cancer treated with chemotherapy and EGFR directed antibodies in
six randomized trials. Ann Oncol. 28:1713–1729. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen CP, Ke TW, Cheng R and Wang JY:
Ramucirumab in the second-line treatment of metastatic colorectal
cancer: A narrative review of literature from clinical trials.
Transl Cancer Res. 9:5645–5654. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tejpar S, Stintzing S, Ciardiello F,
Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann
V: Prognostic and predictive relevance of primary tumor location in
patients with RAS wild-type metastatic colorectal cancer:
Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA
Oncol. 3:194–201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshihiro T, Kusaba H, Makiyama A,
Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T,
Takayoshi K, et al: Efficacy and safety of ramucirumab plus
modified FOLFIRI for metastatic colorectal cancer. Int J Clin
Oncol. 24:508–515. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Holmes K, Roberts OL, Thomas AM and Cross
MJ: Vascular endothelial growth factor receptor-2: Structure,
function, intracellular signalling and therapeutic inhibition. Cell
Signal. 19:2003–2012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jayson GC, Kerbel R, Ellis LM and Harris
AL: Antiangiogenic therapy in oncology: Current status and future
directions. Lancet. 388:518–529. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu C, Ren X, Liu D and Zhang C:
Oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Toxicology. 460:1528822021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fontana RJ: Pathogenesis of idiosyncratic
drug-induced liver injury and clinical perspectives.
Gastroenterology. 146:914–928. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mudd TW and Guddati AK: Management of
hepatotoxicity of chemotherapy and targeted agents. Am J Cancer
Res. 11:3461–3474. 2021.PubMed/NCBI
|
|
20
|
Björnsson ES: Hepatotoxicity by drugs: The
most common implicated agents. Int J Mol Sci. 17:2242016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okuno M, Hatano E, Nakamura K,
Miyagawa-Hayashino A, Kasai Y, Nishio T, Seo S, Taura K and Uemoto
S: Regorafenib suppresses sinusoidal obstruction syndrome in rats.
J Surg Res. 193:693–703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Overman MJ, Ferrarotto R, Raghav K, George
B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, et
al: The addition of bevacizumab to oxaliplatin-based chemotherapy:
Impact upon hepatic sinusoidal injury and thrombocytopenia. J Natl
Cancer Inst. 110:888–894. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
